Logo image
Statins in candidemia: clinical outcomes from a matched cohort study
Journal article   Open access   Peer reviewed

Statins in candidemia: clinical outcomes from a matched cohort study

Graeme N Forrest, Angela M Kopack and Eli N Perencevich
BMC infectious diseases, Vol.10(1), pp.152-152
06/04/2010
DOI: 10.1186/1471-2334-10-152
PMCID: PMC2894022
PMID: 20525374
url
https://doi.org/10.1186/1471-2334-10-152View
Published (Version of record) Open Access

Abstract

HMG CoA reductase inhibitors (statins) in patients with bacteremic sepsis have shown significant survival benefits in several studies. There is no data on the effect of statins in candidemic patients, however in-vitro models suggest that statins interfere with ergesterol formation in the wall of yeasts. This retrospective matched- cohort study from 1/2003 to 12/2006 evaluated the effects of statins on patients with candidemia within intensive care units. Statin-users had candidemia as a cause of their systemic inflammatory response and were on statins throughout their antifungal therapy, while non-statin users were matched based on age +/- 5 years and co-morbid factors. Primary analysis was 30-day survival or discharge using bivariable comparisons. Multivariable comparisons were completed using conditional logistic regression. All variables with a p-value less than 0.10 in the bivariable comparisons were considered for inclusion in the conditional logistic model. There were 15 statin-users and 30 non-statin users that met inclusion criteria, all with similar demographics and co-morbid conditions except the statin group had more coronary artery disease (P < 0.01) and peripheral vascular disease (P = 0.03) and lower median APCAHE II scores (14.6 vs 17, p = 0.03). There were no differences in duration of candidemia, antifungal therapy or Candida species between the groups. Statins were associated with lower mortality on bivariable (OR 0.09, 95% CI 0.11-0.75, p = 0.03) and multivariable (OR 0.22, 95% CI 0.02-2.4, p = 0.21) analyses compared to controls; although, in the latter the protective effect lacked statistical significance. In our small, single-center matched-cohort study, statins may provide a survival benefit in candidemia, however further studies are warranted to validate and further explore this association.
Intensive Care Units Humans Middle Aged Candidiasis - mortality Male Treatment Outcome Case-Control Studies Fungemia - mortality Antifungal Agents - therapeutic use Anticholesteremic Agents - therapeutic use Time Factors Candidiasis - drug therapy Fungemia - drug therapy Female Aged Retrospective Studies Fungemia - pathology Candidiasis - pathology APACHE Cohort Studies

Details

Metrics

Logo image